More than 7 million Americans may be gaining healthcare coverage through Obamacare, but that doesn't mean they will be able
to obtain needed medicines. Despite provisions in the Affordable Care Act (ACA) that require qualified health plans to cover
"basic" benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.
These developments were discussed last month at the annual meeting of the Pharmaceutical Research and Manufacturers of America
(PhRMA) in Washington, D.C. The need to better communicate the value of medicines and to shift the debate from costs and prices
was a major theme. Speakers were optimistic about the enormous potential for new biopharmaceutical discovery, but predicted
this could be limited by curbs on research funding and on drug reimbursement.
A report for PhRMA by Battelle put coverage and payment policies at the top of the list of issues predicted to limit biopharmaceutical
innovation and industry growth over the next ten years. The recent administration proposal to drop certain "protected drug
classes" in Medicare Part D is a sign of the problem, noted Robert Hugin, Celgene CEO and former PhRMA chairman, at a press
briefing. He observed that high cost-sharing raises questions about whether new exchange plans will provide appropriate coverage,
and whether these strategies will migrate to commercial plans.
These concerns were highlighted at a panel on how health reform is reshaping pharmacy benefits, as exchange plans establish
narrow formularies and specialty pharmacy tiers with steep coinsurance rates. Patient advocates cited plans that put all drugs
for HIV/AIDS and hepatitis in the top specialty tier, which in some cases carry 50% coinsurance rates and excessive prior
authorization requirements. And with out-of-pocket maximums exceeding $6,000 for low-cost bronze plans, many beneficiaries
cannot afford needed medicines. These high cost-sharing benefit designs, moreover, could have "a ripple effect" if such strategies
become "the norm" for commercial plans, noted Mark Velleca, executive VP at the Leukemia and Lymphoma Society.
Chet Burrell, CEO of CareFirst BlueCross BlueShield of Washington, D.C., Maryland, and Virginia, offered an alternative approach.
He explained that insurers are looking for ways to better manage pharmacy spending, which now exceeds outlays for inpatient
care for his organization with the rise in specialty medicines. Burrell explained that the ACA requiring guaranteed issue
and community rating, insurers cannot offer lower rates to patients who adopt wellness programs that keep them out of hospitals.
What value in a $1,000 pill?
So CareFirst is proposing to control spending on patients with multiple chronic conditions by waiving cost sharing in 2015
for those very sick beneficiaries who agree to adhere to a special care management program supervised by a physician. He acknowledged
that many actuaries fear this approach will fail to achieve savings. But if it works, Burrell predicted, others may adopt
Another strategy is for states and regulators to set tighter limits on cost-sharing. Maryland recently enacted a $150 limit
on co-pays for specialty drugs, and other states are looking at similar measures. Such a policy sets a level playing field
for insurers and may prevent a "race to the bottom" in the drug coinsurance department.
Yet, the federal government is leery about setting limits on cost-sharing for fear that will drive up premiums, noted Jonathan
Blum, principal deputy administrator of the Centers for Medicare and Medicaid Services (CMS). He acknowledged concerns about
"true access" to benefits and said that CMS will be monitoring how well plans comply with policies designed to prevent discrimination
against older, sicker patients. CMS issued guidance last month advising insurers that compliance reviews will scrutinize marketing
practices and benefit designs that deter less healthy individuals from purchasing a plan.
Yet, that's just what occurs with plans that place whole classes of necessary medicines in the specialty tier with high coinsurance,
said Carl Schmid of The AIDS Institute, who urged CMS to do more to halt such tactics. If there's no enforcement now, he queried,
"who will stop the 'good' plans this year from becoming 'bad plans' next year?"
Broader changes in pharmacy benefit design are needed, observed Jim Robinson, president of Astellas US. He recalled that tiered
benefit plans gained traction under Medicare Part D, along with the $600 price definition for specialty drugs. He and others
want to see that threshold revised upward, and co-pays replace coinsurance for pricey therapies.
Coupons & controls
Higher cost-sharing also puts pressure on pharma companies to maintain drug co-pay assistance programs, long sponsored by
marketers to help low-income and uninsured patients obtain brand medicines. While co-pay vouchers and coupons are accepted
by commercial plans, they are considered "kickbacks" to prescribers under government-funded programs such as Medicare and
Pharma companies may channel patient support through non-profits that independently dispense the assistance to needy individuals.
But uncertainty about whether CMS considers plans sold on exchanges as "federal plans" that cannot accept industry financial
assistance has prompted some manufacturers to hold off on co-pay assistance for ACA beneficiaries; other firms continue to
offer co-pay support pending a clear CMS ruling that this is illegal.
Meanwhile, pharmacy benefit managers (PBMs) and insurers seek new strategies for controlling outlays for specialty meds, which
are expected to reach $235 billion by 2018, according to a new report by Milliman for CVS Caremark. The analysts propose that
insurers shift prescription drug coverage from medical to pharmacy benefits, which can better utilize formulary tiers and
utilization management to control costs. Savings close to 20% would come from revising reimbursement strategies for certain
self-administered drugs obtained from pharmacies, as opposed to doctors' offices. Such a shift, though, runs counter to pharma
efforts to highlight how outlays for medications can reduce overall healthcare spending—and provide value to the healthcare
Jill Wechsler is Pharm Exec's Washington correspondent. She can be reached at